Q32 Bio (QTTB) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Q32 Bio will report Q1 2026 results before the market opens on May 7, with analysts forecasting EPS of ($0.68) and revenue of $39.735 million; a conference call is scheduled for May 14 at 9:30 AM ET.
• Last quarter the company beat estimates with $3.65 EPS and $53.74 million in revenue, but analysts now expect roughly -3 EPS for the current and next fiscal years while the stock opened at $5.50 and was down 3.8%.
• Insiders have been selling (CEO Jodie Pope Morrison sold 9,896 shares, a 10% reduction of her stake) even though insiders still own about 40%, and analyst opinions are mixed—ranging from sell to strong-buy with a consensus target of $13.00.

Q32 Bio (NASDAQ:QTTB - Get Free Report) is expected to announce its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.68) per share and revenue of $39.7350 million for the quarter. Investors can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, May 14, 2026 at 9:30 AM ET.

Q32 Bio (NASDAQ:QTTB - Get Free Report) last released its earnings results on Tuesday, March 10th. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of ($1.06) by $4.71. The business had revenue of $53.74 million for the quarter. On average, analysts expect Q32 Bio to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Q32 Bio Stock Down 3.8%

QTTB stock opened at $5.50 on Thursday. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.85 and a quick ratio of 4.85. Q32 Bio has a 1-year low of $1.35 and a 1-year high of $8.05. The firm has a fifty day moving average price of $5.83 and a two-hundred day moving average price of $4.12. The firm has a market cap of $80.46 million, a price-to-earnings ratio of 2.39 and a beta of -0.05.

Analyst Upgrades and Downgrades

Several analysts have weighed in on QTTB shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Q32 Bio in a research note on Friday, January 9th. HC Wainwright reiterated a "buy" rating and set a $13.00 target price on shares of Q32 Bio in a research note on Tuesday, March 10th. Finally, Zacks Research upgraded shares of Q32 Bio from a "hold" rating to a "strong-buy" rating in a research note on Thursday, March 12th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $13.00.

Insiders Place Their Bets

In related news, CEO Jodie Pope Morrison sold 9,896 shares of Q32 Bio stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $4.51, for a total value of $44,630.96. Following the sale, the chief executive officer directly owned 89,104 shares in the company, valued at $401,859.04. This trade represents a 10.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last 90 days, insiders have sold 16,706 shares of company stock valued at $75,344. Company insiders own 40.00% of the company's stock.

Institutional Trading of Q32 Bio

Several hedge funds have recently bought and sold shares of QTTB. Opaleye Management Inc. bought a new stake in Q32 Bio in the 4th quarter valued at about $708,000. Renaissance Technologies LLC lifted its position in Q32 Bio by 110.6% in the 4th quarter. Renaissance Technologies LLC now owns 99,600 shares of the company's stock valued at $331,000 after purchasing an additional 52,300 shares during the last quarter. Jane Street Group LLC bought a new stake in Q32 Bio in the 2nd quarter valued at about $69,000. AQR Capital Management LLC acquired a new stake in Q32 Bio in the first quarter worth about $68,000. Finally, Two Sigma Investments LP acquired a new stake in Q32 Bio in the third quarter worth about $62,000. 31.32% of the stock is currently owned by institutional investors.

About Q32 Bio

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.